Jan J. Melenhorst

Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy

Elena Sotillo, David M. Barrett, Kathryn L. Black et al. · Cancer Discovery · 2015 · 1.2K citations · Full text

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Stephen J. Schuster, Jakub Svoboda, Sunita D. Nasta et al. · Blood · 2015 · 78 citations

Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer.

Gregory L. Beatty, Mark H. O’Hara, Anne Marie Nelson et al. · Journal of Clinical Oncology · 2015 · 53 citations

Antitumor Activity, Immunology, Immunoediting +26

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

Noelle V. Frey, Bruce L. Levine, Simon F. Lacey et al. · Blood · 2014 · 45 citations

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Susan R. Rheingold, Lanyi Nora Chen, Shannon L. Maude et al. · Blood · 2015 · 43 citations